SCHEMBL16768178

SCHEMBL16768178

C=C1CCC(n2c(CC)nc3cccc(C)c3c2=O)C(=O)N1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 5/20 0.48
CRBN Q96SW2 5/20 0.48
IKZF3 Q9UKT9 2/20 0.48
TNF P01375 1/20 0.48
IL1B P01584 1/20 0.48
PIK3CD O00329 3/20 0.38
ELANE P08246 4/20 0.34
AGTR1 P30556 1/20 0.34
PPARG P37231 1/20 0.34
PARP1 P09874 1/20 0.34
PARP14 Q460N5 1/20 0.33
HRH3 Q9Y5N1 2/20 0.33
KCNH2 Q12809 1/20 0.33
PIK3CG P48736 1/20 0.33
HTR1A P08908 1/20 0.33
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12638377 0.90 DDB1 (0.46) DDB1CRBNIKZF3TNFIL1B
SCHEMBL282755 0.89 DDB1 (0.61) DDB1CRBNIKZF3TNFIL1B
SCHEMBL12638348 0.87 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL16768175 0.87 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL16768176 0.85 DDB1 (0.50) DDB1CRBNIKZF3TNFIL1B
SCHEMBL13405473 0.83 DDB1 (0.48) DDB1CRBNIKZF3TNFIL1B
SCHEMBL16768179 0.82 DDB1 (0.48) DDB1CRBNIKZF3TNFIL1B
SCHEMBL19525976 0.82 DDB1 (0.60) DDB1CRBNIKZF3TNFIL1B
SCHEMBL282870 0.80 CRBN (0.57) DDB1CRBNIKZF3TNFIL1B
SCHEMBL15745529 0.77 CRBN (0.80) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362660-A1 CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT CELGENE CORP (US) 2017-12-21 US disclosed
US-9587281-B2 Cereblon isoforms and their use as biomarkers for therapeutic treatment CELGENE CORPORATION (US) 2017-03-07 US disclosed
US-20150152511-A1 CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT CELGENE CORPORATION 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362660-A1 CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT CRBN, CDR2, PMP22 DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885
US-20150152511-A1 CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT CRBN, CDR2, PMP22 DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.